Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy (Q38615337)

4 September 2017

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. (English)

1 reference

4 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Saeed K. Alzghari

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Gary W Jean

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Cindy Huynh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Devin B Lowe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

English

0 references

publication date

1 October 2015

1 reference

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

963-976

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

Cancer-related inflammation

5 June 2020

cites work

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

A history of cancer chemotherapy

21 January 2018

1 reference

Cancer immunotherapy comes of age

21 January 2018

1 reference

Monoclonal antibodies as therapeutic agents for cancer

21 January 2018

1 reference

Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis

21 January 2018

1 reference

Application of IL-2 and other cytokines in renal cancer

21 January 2018

1 reference

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

Mechanisms of immune evasion by tumors

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

Therapy for metastatic melanoma: the past, present, and future.

21 January 2018

1 reference

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

21 January 2018

1 reference

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

Toxicities of Immunotherapy for the Practitioner

21 January 2018

1 reference

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

21 January 2018

1 reference

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

21 January 2018

1 reference

Ipilimumab in patients with melanoma and autoimmune disease

21 January 2018

1 reference

Ipilimumab and its toxicities: a multidisciplinary approach

21 January 2018

1 reference

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

Improved overall survival in melanoma with combined dabrafenib and trametinib

21 January 2018

1 reference

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

21 January 2018

1 reference

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

Immune evasion in cancer: Mechanistic basis and therapeutic strategies.

21 January 2018

1 reference

Immune checkpoint blockade: a common denominator approach to cancer therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1643

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26497482%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference